The cat as a model for human nutrition and disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 5, 2006, Pages 584-588

  Hoenig, Margarethe ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Adiponectin; Amyloid; Feline diabetes; Islet amyloid polypeptide; Leptin

Indexed keywords

ADIPONECTIN; AMYLIN; CYTOKINE; FATTY ACID; GLIPIZIDE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; INSULIN; LEPTIN; LIPOPROTEIN LIPASE; MESSENGER RNA; SULFONYLUREA DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

AMYLOIDOSIS; CAT; DIABETES MELLITUS; DISEASE MODEL; GLUCOSE METABOLISM; INSULIN RELEASE; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; NUTRITION; OBESITY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; BLOOD GLUCOSE; CATS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; INSULIN; LIPID METABOLISM; OBESITY;

FELIDAE;

EID: 33747487423     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000241668.30761.69     Document Type: Review

References (63)

1. Panciera DL, Thomas CB, Eicker SW, Atkins CE. Epizootiologic patterns of diabetes mellitus in cats: 333 cases (1980-1986). J Am Vet Med Assoc 1990; 197:154-158.
2. Scarlett JM, Donoghue S. Associations between body condition and disease in cats. J Am Vet Med Assoc 1998; 212:1725-1731.
3. Lund EM, Armstrong PJ, Kirk CA, Klausner JS. Prevalence and risk factor for obesity in adult cats from private US veterinary practices. Int J Appl Res Vet Med 2005; 3:88-96. •This paper examines risk factors for overweight and obese cats in a population of more than 8000 cats.
4. Schaer M. Diabetes mellitus in the cat. J Am Anim Hosp Assoc 1973; 9:548-551.
5. Rand JS, Bobbermien LM, Hendrikz JK, Copland M. Over representation of Burmese cats with diabetes mellitus. Aust Vet J 1997; 75:402-405.
6. Hoenig M, Thomaseth K, Brandao J, et al. Assessment and mathematical modeling of glucose turnover and insulin sensitivity in lean and obese cats. Domest Anim Endocrinol 2006; Jan 11 [Epub ahead of print]. •This paper describes mathematical modeling and non-steady-state analysis to assess effects of obesity on glucose turnover, glycolysis/glycogen synthesis, insulin sensitivity, and inhibition of endogenous glucose production in lean and obese cats.
7. Hoenig M, Alexander S, Holson J, Ferguson DC. Influence of glucose dosage on interpretation of intravenous glucose tolerance tests in lean and obese cats. J Vet Intern Med 2002; 16:529-532.
8. Hoenig M, Hall G, Ferguson D, et al. A feline model of experimentally induced islet amyloidosis. Am J Pathol 2000; 157:2143-2150.
9. Wilkins CE, Long RC Jr, Waldron M, et al. Assessment of the influence of fatty acids on indices of insulin sensitivity and myocellular lipid content by use of magnetic resonance spectroscopy in cats. Am J Vet Res 2004; 65:1090-1099.
10. Brennan CL, Hoenig M, Ferguson DC. GLUT4 but not GLUT1 expression decreases early in the development of feline obesity. Domest Anim Endocrinol 2004; 26:291-301.
11. Hoenig M, Caffall ZF, McGraw RA, Ferguson DC. Cloning, expression and purification of feline proinsulin. Domest Anim Endocrinol 2006; 30:28-37. •This paper describes the cloning, expression, and purification of feline proinsulin.
12. Haffner SM, Gonzalez C, Mykkänen L, Stern M. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study. Diabetologia 1997; 40:830-837.
13. Haffner SM, Stern MP,Miettinen H, et al. Higher proinsulin and specific insulin are both associated with a parental history of diabetes in nondiabetic Mexican-American subjects. Diabetes 1995; 44:1156-1160.
14. Hermann LS, Ranstam J, Vaaler S, Melander A. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. Diabetes Obes Metab 1999; 1:227-232.
15. Backus RC, Havel PJ, Gingerich RL, Rogers QR. Relationship between serum leptin immunoreactivity and body fat mass as estimated by use of a novel gas-phase Fourier transform infrared spectroscopy deuterium dilution method in cats. Am J Vet Res 2000; 61:796-801.
16. Hoenig M, Ferguson DC. Effect of darglitazone on glucose clearance and lipid metabolism in obese cats. Am J Vet Res 2003; 64:1409-1413.
17. Yildiz BO, Haznedaroglu IC. Rethinking leptin and insulin action: therapeutic opportunities for diabetes. Int J Biochem Cell Biol 2006; 38:820-830. •This review summarizes the clinical applications of leptin, particularly emphasizing the effects of leptin on glucose homeostasis.
18. Kershaw E, Flier J. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548-2556.
19. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin - the classical, resistin - the controversial, adiponectin: the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19:525-546. •This paper reviews recent topics in adipocytokine research.
20. Arita Y, Kihara S, Ouchi N, Takahashi M. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79-83.
21. Butler PC, Chou J, Carter WB, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990; 39:752-756.
22. Fehmann HC, Weber V, Goke R, et al. Cosecretion of amylin and insulin from isolated rat pancreas. FEBS Lett 1990; 262:279-281.
23. Gasa R, Gomis R, Casamitjana R, Novialis A. High glucose concentration favors the selective secretion of islet amyloid polypeptide through the constitutive secretory pathway in human pancreatic islets. Pancreas 2001; 22:307-310.
24. Johnson KH, O'Brien TD, Betsholtz C, Westermark P. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 1989; 321:513-518.
25. Johnson KH, Hayden DW, O'Brien TD, Westermark P. Spontaneous diabetes mellitus-islet amyloid complex in adult cats. Am J Pathol 1986; 125:416-419.
26. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999; 48:241-253.
27. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-110.
28. Ritzel RA, Butler PC. Replication increases β-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 2003; 52:1701-1708.
29. Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes? Diabetologia 2004; 47:157-169.
30. O'Brien TD, Westermark P, Johnson KH. Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 1991; 40:1701-1706.
31. Toshimori H, Narita R, Nakazato M, et al. Islet amyloid polypeptide in insulinoma and in the islets of the pancreas of nondiabetic and diabetic subjects. Virchows Arch A Pathol Anat Histopathol 1991; 418:411-417.
32. O'Brien TD, Butler AE, Roche PC, et al. Islet amyloid polypeptide in human insulinomas: evidence for intracellular amyloidogenesis. Diabetes 1994; 43:329-336.
33. Hoenig M, Ferguson DC. Effects of neutering on hormonal concentrations and energy requirements in male and female cats. Am J Vet Res 2002; 63:634-639.
34. Hoenig M, Wilkins C, Holson JC, Ferguson DC. Effects of obesity on lipid profiles in neutered male and female cats. Am J Vet Res 2003; 64:299-303.
35. Hoenig M, Thomaseth K, Waldron M, Ferguson DC, Fatty acid turnover, substrate oxidation, and heat production in lean and obese cats during the euglycemic hyperinsulinemic clamp. Domest Anim Endocrinol (in press).
36. Kooner JS, Baliga RR, Wilding J, et al. Abdominal obesity, impaired non-esterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction. Arterioscler Thromb Vasc Biol 1998; 18:1021-1026.
37. Ravussin E, Bogardus C, Schwartz RS, et al. Thermic effect of infused glucose and insulin in man: decreased response with increased insulin resistance in obesity and non insulin dependent diabetes mellitus. J Clin Invest 1983; 72:893-902.
38. Pedersen SB, Borglum JD, Schmitz O, et al. Abdominal obesity is associated with insulin resistance and reduced glycogen synthetase activity in skeletal muscle. Metabolism 1993; 42:998-1005.
39. Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 1993; 9:452-459.
40. Evans DJ, Murray R, Kissebah AH. Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal, and insulin binding: effects of obesity and body fat topography. J Clin Invest 1984; 74:1515-1525.
41. Deen D. Metabolic syndrome: time for action. Am Fam Physician 2004; 69:2875-2882.
42. Sennello KA, Schulman RL, Prosek R, Siegel AM. Systolic blood pressure in cats with diabetes mellitus. J Am Vet Med Assoc 2003; 223:198-201.
43. Watson TD, Butterwick RF, McConnell M. Development of methods for analyzing plasma lipoprotein concentrations and associated enzyme activities and their use to measure the effects of pregnancy and lactation in cats. Am J Vet Res 1995; 56:289-296; 1995.
44. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113:20-29. •This paper examines the sex-specific cross-sectional relations of small low-density lipoprotein particle numbers determined by nuclear magnetic resonance spectroscopy to the presence of the metabolic syndrome and its components in 2993 Framingham Heart Study participants.
45. Hoenig M, McGoldrick JB, deBeer M, et al. Activity and tissue-specific expression of lipases and tumor-necrosis factor α in lean and obese cats. Domest Anim Endocrinol 2006; 30:333-344. •This study describes the measurement of postheparin plasma activity of LPL and hepatic lipase and fat and muscle activity of LPL in neutered lean and obese cats. In addition, lipoprotein lipase, HSL, and TNF-α mRNA were measured in muscle and fat tissue with real-time polymerase chain reaction using primers for feline LPL, HSL, and TNF.
46. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95:2111-2119.
47. Perseghin G, Scifo P, De Cobelli F, et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48:1600-1606.
48. Boden G, Lebed B, Schatz M. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001; 50:1612-1617.
49. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol 2003; 111:121-124.
50. McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51:7-18.
51. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277:50230-50236.
52. Frank G, Anderson W, Pazak H, et al. Use of a high protein diet in the management of feline diabetes mellitus. Vet Ther 2001; 2:238-246.
53. Tanaka A, Inoue A, Takeguchi A, et al. Comparison of expression of glucokinase gene and activities of enzymes related to glucose metabolism in livers between dog and cat. Vet Res Commun 2005; 29:477-485. •This paper describes analysis of feline liver and pancreas for the expression of glucokinase and of the activities of glycolytic and gluconeogenic enzymes in feline and canine liver.
54. Washizu T, Tanaka A, Sako T, et al. Comparison of the activities of enzymes related to glycolysis and gluconeogenesis in the liver of dogs and cats. Res Vet Sci 2005; 67:203-204.
55. Ballard FJ. Glucose utilization in mammalian liver. Comp Biochem Physiol 1965; 14:437-443.
56. Rogers QR, Morris JG, Freedand RA. Lack of hepatic enzymatic adaptation to low and high levels of dietary protein in the adult cat. Enzyme 1977; 22:348-356.
57. Silva SVPS, Mercer JR. Effect of protein intake on amino acid catabolism and gluconeogenesis by isolated hepatocytes from the cat (Felis domestica). Comp Biochem Physiol 1985; 80B:603-607.
58. Russell K, Murgatroyd PR, Batt RM. Net protein oxidation is adapted to dietary protein intake in domestic cats (Felis silvestris catus). J Nutr 2002; 132:456-460.
59. Lester T, Czarnecki-Mauldin G, Lewis D. Cats increase fatty acid oxidation when isocalorically fed meat-based diets with increasing fat content. Am J Phsyiol Regul Integr Comp Physiol 1999; 277:R878-R886.
60. Hoenig M, Waldron M, Ferguson DC. Effect of a high and low carbohydrate diet on respiratory exchange ratio, and heat production, in lean, and obese cats before and after weight loss. Compendium Continuing Ed Suppl Pract Vet 2006; 4:10.
61. Hoenig M, Thomaseth K, Waldron M, Ferguson DC. Effect of a high- and low-carbohydrate diet on insulin sensitivity in lean and obese cats before and after weight loss. Compendium Continuing Ed Suppl Pract Vet 2006; 4:9.
62. Szabo J, Ibrahim WH, Sunvold GD, et al. Influence of dietary protein and lipid on weight loss in obese ovariohysterectomized cats. Am J Vet Res 2000; 61:559-565.
63. Laflamme DP, Hannah SS. Increased dietary protein promotes fat loss and reduces loss of lean body mass during weight loss in cats. Int J Appl Res Vet Med 2005; 3:62-68. •This study evaluated whether increased dietary protein would minimize loss of lean mass in cats during weight loss.